Hematology
News
Ibrutinib-venetoclax found highly active in hard-to-treat CLL
Trial results suggest the two drugs may have synergistic efficacy when used together, and raise the possibility of achieving MRD negativity with...
News
Gaps in patient-provider survivorship communication persist
Over a recent 5-year period, there was little change in the percentages of patients who reported not having any detailed discussion with providers...
Conference Coverage
SC daratumumab deemed feasible for every multiple myeloma patient
CHICAGO – In the COLUMBA trial, subcutaneous daratumumab proved noninferior to intravenous daratumumab in overall response rate and maximum trough...
News
Another study supports safety of 2-cm margins for thick melanomas
Similar outcomes seen with 4-cm and 2-cm excision margins for melanomas greater than 2 mm.
Conference Coverage
Ibrutinib tops chlorambucil against CLL
AMSTERDAM – The Bruton’s tyrosine kinase inhibitor was associated with a halving of risk for death, compared with chlorambucil.
Conference Coverage
R2-CHOP doesn’t improve survival in DLBCL
LUGANO, SWITZERLAND – The ROBUST trial is the latest in a long line of studies that failed to show improvement in outcomes with the addition of a...
News
CNS-directed therapy appears more effective for synDLBCL
Two-year survival rates were superior among patients who received CNS-intensive therapy.
News
FDA approves Xpovio for relapsed/refractory multiple myeloma
The oral therapy was approved for patients who have received at least four prior therapies and whose disease is resistant to several other forms...
Conference Coverage
Cell count ratios appear to predict thromboembolism in lymphoma
AMSTERDAM – The findings mean clinicians can look to complete blood count for answers on thromboembolism risk.
Conference Coverage
For tough AML, half respond to selinexor plus chemotherapy
AMSTERDAM – The addition of selinexor looks promising in relapsed/refractory AML, but Karyopharm Therapeutics will be focusing first on approval...
